Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

ADC Payload

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Cytotoxin (21) ADC Linker (13) Drug-Linker Conjugates for ADC (16) Antibody-Drug Conjugates (ADCs) (12) Apoptosis (1) Bacterial (2) Biochemical Assay Reagents (1) c-Met/HGFR (1) DNA Alkylator/Crosslinker (5) Drug Metabolite (1) EGFR (3) FGFR (1) Glucocorticoid Receptor (1) IFNAR (1) Isotope-Labeled Compounds (1) Mesothelin (1) Microtubule/Tubulin (6) Mucin (1) NAMPT (3) PD-1/PD-L1 (1) PROTAC Linkers (1) Toll-like Receptor (TLR) (1) Topoisomerase (2)
By Research Areas:	Cancer (61) Inflammation/Immunology (2) Metabolic Disease (1)
Click Chemistry:	ADC Synthesis (1) DBCO (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: ADC Cytotoxin ADC Antibody ADC Linker Drug-Linker Conjugates for ADC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148128

TAM470	Microtubule/Tubulin ADC Cytotoxin	Cancer
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .

HY-15581

MMAD Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10	Microtubule/Tubulin ADC Cytotoxin	Cancer
MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).

HY-132162

7-MAD-MDCPT	ADC Cytotoxin	Cancer
7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .

HY-164787

N-MeVal-Val-Dil-Dap-2-(pyridin-3-yl)ethanamine	ADC Cytotoxin Microtubule/Tubulin	Cancer
N-MeVal-Val-Dil-Dap-2-(pyridin-3-yl)ethanamine (Compound 14) is a tubulin polymerization inhibitor that can be used as an ADC payload .

HY-156249

NMS-P528	ADC Cytotoxin	Cancer
NMS-P528 is a Duocarmycin derivative that can be used as an **ADC payload**. NMS-P528 can be used to synthesize NMS-P945 .

HY-132158

MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin	Drug-Linker Conjugates for ADC	Cancer
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC) .

HY-107502

Cryptophycin analog 1	Antibody-Drug Conjugates (ADCs)	Cancer
Cryptophycin analog 1 is an ADC payload. Cryptophycin analog 1 shows anticancer activity. Cryptophycin analog 1 displays cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1 .

HY-164707

MC7	Drug-Linker Conjugates for ADC	Cancer
MC7 is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-402237) .

HY-164705

Mal-Toxophore	Drug-Linker Conjugates for ADC	Cancer
Mal-Toxophore is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164759) .

HY-169324

APL-1092 Mal-Exo-EEVC-Exatecan	Drug-Linker Conjugates for ADC	Cancer
APL-1092 (Mal-Exo-EEVC-Exatecan) is a drug-linker conjugate for ADC, which contains Exatecan (HY-13631) (ADC payload) and a linker .

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	ADC Cytotoxin	Cancer
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effcts. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-156756

7-Hydroxymethyl-10,11-MDCPT	ADC Cytotoxin	Others
7-Hydroxymethyl-10,11-MDCPT is a payload that can be used for *ADC* synthesis .

HY-101127

SGD-1882 PBD dimer	ADC Cytotoxin	Cancer
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.

HY-126663

N-Me-L-Ala-maytansinol	ADC Cytotoxin	Cancer
N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used for making antibody-drug conjugate *(ADC)* .

HY-164706

m-PEG6-Lys-Mal-Toxophore-quinoline	Drug-Linker Conjugates for ADC	Cancer
m-PEG6-Lys-Mal-Toxophore-quinoline is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164760) .

HY-144880

SC209	ADC Cytotoxin EGFR Drug Metabolite	Cancer
SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is the payload of STRO-002 .

HY-164954

ADC Control Human IgG1-McMMAF	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 Human IgG1 kappa, Isotype Control (HY-P99001) and the payload McMMAF (HY-15578).

HY-157078

Eg5-IN-2	ADC Cytotoxin	Cancer
Eg5-IN-2 (Compound Scaffold B (4)) is an Eg5 inhibitor (IC₅₀: < 0.5 nM). Eg5-IN-2 can be used as an ADC payload for synthesis of ADCs .

HY-147408

Rezetecán SHR9265	Topoisomerase ADC Cytotoxin	Cancer
Rezetecán (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecán can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload .

HY-101141

sulfo-SPDB-DM4	Drug-Linker Conjugates for ADC	Cancer
sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.

HY-154915

MC-EVCit-PAB-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-164730

Epratuzumab Tesirine ADCT-602; hLL2-Cys-PBD	Antibody-Drug Conjugates (ADCs)	Cancer
Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG3249 .

HY-128952

Tesirine 3 Publications Verification SG3249	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

HY-101161

SG3199 2 Publications Verification	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249) .

HY-12460

SPDB-DM4	Drug-Linker Conjugates for ADC	Cancer
SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.

HY-153909

SMP-33693	Drug-Linker Conjugates for ADC	Cancer
SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-159774

ADC Control human IgG1-DM1	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control human IgG1-DM1 is the ADC control, which is composed of Human IgG1 kappa, Isotype Control (HY-P99001) and the linker-payload conjugate SMCC-DM1 (HY-101070) .

HY-153908

SMP-93566	Drug-Linker Conjugates for ADC	Cancer
SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-145078

PNU-EDA-Gly5	Drug-Linker Conjugates for ADC	Cancer
PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5 .

HY-171269

Anetumab-MMAE	ADC Antibody Mesothelin	Cancer
Anetumab-MMAE is an antibody-drug conjugate (ADC) (Anetumab antibody (HY-P99352), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is an anti-mesothelin (MSLN) antibody.

HY-163672

Glucocorticoid receptor modulator 3	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology
Glucocorticoid receptor modulator 3 (Payload 6) is a thioester-containing glucocorticoid receptor modulator (IC₅₀=0.6 nM). Glucocorticoid receptor modulator 3 is designed to inactivate unconjugated payloads rapidly through liver metabolism, thereby minimizing systemic exposure. Glucocorticoid receptor modulator 3 can be utilized in the development of antibody-drug conjugates (ADCs) targeting autoimmune diseases .

HY-171270

Clivatuzumab-MMAE	Antibody-Drug Conjugates (ADCs) Mucin	Cancer
Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) (Clivatuzumab antibody (HY-P99968), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is a humanized anti-mucin monoclonal antibody.

HY-156756S

7-Hydroxymethyl-10,11-MDCPT-d5	Isotope-Labeled Compounds ADC Cytotoxin	Others
7-Hydroxymethyl-10,11-MDCPT-d₅ is deuterium labeled 7-Hydroxymethyl-10,11-MDCPT, which is a is a payload that can be used for *ADC* synthesis .

HY-135901

Py-MPB-amino-C3-PBD	ADC Cytotoxin Bacterial	Cancer
Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

HY-112616

NAMPT inhibitor-linker 2	NAMPT Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 2 is a agent-linker conjugates for *ADC, composed of an NAMPT* inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC₅₀s of <7 pM and 40 pM, respectively.

HY-112615

NAMPT inhibitor-linker 1	Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 1 is a agent-linker conjugates for *ADC, composed of an NAMPT* inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC₅₀s of <3 pM and 9 pM, respectively.

HY-W190913

DBCO-PEG4-Val-Cit-PAB-PNP	ADC Linker	Cancer
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.

HY-103688

N-Ac-γ-Calicheamicin-AcBut-NHS ester	ADC Cytotoxin	Cancer
AcBut-N-Ac-γ-Calicheamicin is an *ADC* cytotoxic payload that induces cell cycle arrest and apoptosis by causing DNA double-strand breaks. AcBut-N-Ac-γ-Calicheamicin is primarily used in the synthesis of antibody-drug conjugates (ADC) and holds promise for research in the field of cancer, including acute lymphoblastic leukemia (ALL) and other hematological malignancies .

HY-W800814

Azido-PEG8-Amido-Val-Cit-PAB	ADC Linker	Cancer
Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.

HY-130161

m-PEG4-Br	ADC Linker PROTAC Linkers	Cancer
m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907). m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency . m-PEG4-Br also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.

HY-W800622

Fmoc-PEG4-Val-Cit-PAB-OH	ADC Linker	Cancer
Fmoc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800625

Boc-PEG4-Val-Cit-PAB-OH	ADC Linker	Cancer
Boc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800621

Fmoc-PEG2-Val-Cit-PAB-OH	ADC Linker	Cancer
Fmoc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine for use in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800623

Fmoc-PEG6-Val-Cit-PAB-OH	ADC Linker	Cancer
Fmoc-PEG6-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800624

Boc-PEG2-Val-Cit-PAB-OH	ADC Linker	Cancer
Boc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-129589

Thailanstatin A 1 Publications Verification	ADC Cytotoxin	Cancer
Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC₅₀=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC₅₀s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC .

HY-147193

Nampt-IN-10 TFA	NAMPT	Cancer
Nampt-IN-10 TFA (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 TFA shows cellular potency to A2780 and CORL23 cells lines with IC₅₀s of 5 and 19 nM, respectively. Nampt-IN-10 TFA can be used as a novel non-antimitotic payload for ADCs .

HY-147193A

Nampt-IN-10 trihydrochloride	NAMPT	Cancer
Nampt-IN-10 trihydrochloride (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 trihydrochloride shows cellular potency to A2780 and CORL23 cell lines with IC₅₀ values of 5 and 19 nM, respectively. Nampt-IN-10 trihydrochloride can be used as a novel non-antimitotic payload for antibody-drug conjugate (ADC) .

HY-147363

DIBAC-GGFG-NH2CH2-Dxd	Drug-Linker Conjugates for ADC	Others
DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates . Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

113 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 113 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Target	Research Area

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P99829

Cofetuzumab pelidotin PF-06647020; ABBV-647; h6M24-vc0101	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting *ADC* comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC₅₀ of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .